TransHeps
@transheps.com
TransHeps - Decreasing drug failures with the right iDILI diagnosis. •iDILI causality assessment for clinical trials •Drug-induced liver injury (DILI) testing •Advanced liver toxicity evaluation •Hepatotoxicity testing solutions •Clinical DILI analysis •Toxicology services for CROs •Liver injury testing for pharma companies •Safety evaluation for biotech startups •Drug development solutions for clinical trial organizations
TransHeps's Company Logos
TransHeps's Brand Colors
Hex Code
Color name
RGB
HSL
CMYK
#FF9626
Sunshade
255, 150, 38
31, 100, 57
0, 41, 85, 0
#FF4962
Radical Red
255, 73, 98
352, 100, 64
0, 71, 62, 0
#000040
Stratos
0, 0, 64
240, 100, 13
100, 100, 0, 75
About TransHeps
TransHeps AG is a pioneering company dedicated to enhancing patient safety through the advancement of drug development. Focused on addressing drug-induced liver injury (DILI), TransHeps provides the MetaHeps assay, a cutting-edge decision-enabling tool for global pharmaceutical companies and regulatory bodies. This innovative assay facilitates precise DILI causality assessments throughout clinical studies, empowering drug developers to make informed decisions and improve therapeutic outcomes.
Founded by a team of experts, including CEO Prof. Armin Wolf and co-founders Martin Birk, Michele Visentin, and Sophia Samodelov, TransHeps stands at the forefront of DILI research and assessment. By prioritizing safety and efficacy, the company plays a crucial role in streamlining the drug development process. Based in Zurich, Switzerland, TransHeps AG is committed to making its technology accessible worldwide, ensuring that safer drugs reach patients faster. For those interested in learning more about their offerings, TransHeps encourages inquiries via their customer service channels.
Company type
Public Company
Year founded
2024
Company size
2-10 employees
